Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, TScan Therapeutics Partner on CDx for T-Cell Receptor Therapy in Solid Tumors

NEW YORK – Tempus announced on Thursday a collaboration with TScan Therapeutics to develop a companion diagnostic test to prospectively assess human leukocyte antigen (HLA) loss in patients' tumors. 

The test would support TScan's screening protocol for its Phase I solid tumor clinical trial that is designed to enable customized mixtures of T-cell receptor engineered T-cell therapies (TCR-Ts) that are administered to patients based on tumor antigen positivity and intact HLA expression, Tempus said in a statement.

TScan plans to enroll patients with solid tumors including non-small cell lung cancer, melanoma, head and neck cancer, ovarian cancer, and cervical cancer. The biopharmaceutical company will use Tempus' xT assay, a 648-gene sequencing panel, to prospectively identify patients with HLA loss in the tumor to select TCR-Ts that can recognize intact HLS genes, Tempus said.

"Utilizing the assay developed in collaboration with Tempus will help determine if the clinical trial participants' tumors have undergone partial HLA loss and so will enable us to choose the most appropriate TCR-Ts that are customized for the patient's tumor antigens and preserved HLA genes," TScan Chief Medical Officer Debora Barton said in a statement. 

"This CDx work is unique because we're looking for information that's not currently in the list of readouts you typically receive from next-generation sequencing of a solid tumor," Tempus Executive VP Michael Yasiejko said in a statement. "Tempus is uniquely positioned to develop a custom pipeline to extract information from standard tests that need to guide TCR-T therapy development and ultimately help identify patients that may benefit from these therapies."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.